Saturday 17 October 2026
Export BLTE’s income statement to Excel — free account
Belite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 40.0% and free cash flow grew 64.7%, each against the same quarter a year earlier.
142.78
9.84
−6.45%
Follow BLTE
Belite Bio, Inc. Sponsored ADR (BLTE) P/E ratio
Belite Bio, Inc. Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KOD Kodiak Sciences Inc. compare | n/m |
| MIRM Mirum Pharmaceuticals, Inc. compare | n/m |
| CGON CG Oncology, Inc. compare | n/m |
| PRAX Praxis Precision Medicines, Inc. compare | n/m |
| IMVT Immunovant, Inc. compare | n/m |
| IOVA Iovance Biotherapeutics, Inc. compare | n/m |
| RYTM Rhythm Pharmaceuticals, Inc. compare | n/m |
| BLTE Belite Bio, Inc. Sponsored ADR | n/m |
| LGND Ligand Pharmaceuticals Incorporated compare | 29.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)